光活化抗癌药物仅在适当波长照射下才体现出抗癌活性，因此可以通过在时间和空间上对光照的控制提高药物对肿瘤的选择性，降低药物毒副作用。Ru(II) arene配合物是一类极具潜力的光活化抗癌药物，但光活化波长过短是限制其临床应用的主要弊端。本项目拟利用在长波长具有强吸光能力的BODIPY类光敏染料修饰Ru(II) arene配合物，借助BODIPY激发单重态到配合物MLCT三重态的能量传递，大幅度延长其光活化波长。BODIPY的修饰还将使Ru(II) arene配合物的细胞成像研究成为可能，并有望发展成为光活化化学疗法和光动力疗法相结合的新型抗癌药物。本项目研究将为基于光诱导配体解离机制的金属配合物光活化抗癌药物的研发提供新思路。

Photoactivated chemotherapy provides the opportunity for control over when and where a drug is activated, resulting in a greater specificity of drug action. Ru(II) arene complexes are one type of appealing photoactivated anti-cancer drugs, however, the short photoactivation wavelength limits their clinical applications. We plan to design and synthesize novel BODIPY-modified Ru(II) arene complexes. The energy transfer from the excited singlet state of the BODIPY chromophore to the 3MLCT state of the complex may be utilized to red shift the photoactivation wavelength of the Ru(II) arene complexes markedly. The modification of BODIPY may also make the cellular imaging of the Ru(II) arene complexes possible. Furthermore, photoactivated chemotherapy and photodynamic therapy may be combined effectively in the BODIPY-modified Ru(II) arene complexes. The research may open a new avenue for the development of more efficient photoactivated anti-cancer agents based on the photoinduced ligand dissociation mechanism.